Navigation Links
Vista Partners Initiates Coverage on ADVENTRX Pharmaceuticals, Inc.; Target Price $7.50
Date:6/22/2011

SAN FRANCISCO, June 22, 2011 /PRNewswire/ -- Vista Partners announced today that it has initiated coverage on ADVENTRX Pharmaceuticals, Inc. (AMEX: ANX) ("The Company" or "ANX"); with a twelve month target price of $7.50. Ross Silver, Principal Analyst at Vista Partners stated, “ANX has a diverse late stage clinical pipeline with two clinical candidates that could serve multi-billion dollar markets and one candidate with a Prescription Drug User Fee Act, or PDUFA, goal date of September 1, 2011 that could lead to approval by FDA as early as this year. ANX is developing a study protocol for ANX-514, a novel emulsion formulation of the chemotherapy drug docetaxel which serves a multi-billion dollar market. The Company is preparing ANX-514 for submission to the FDA and intends to continue discussions with the FDA regarding the planned Phase 3 clinical study and other requirements for approval of ANX-514. The company is developing its protocol for a pivotal Phase III trial scheduled to begin in 2012." Mr. Silver continues, "In April 2011, ANX completed the acquisition of SynthRx, Inc. SynthRx's lead product candidate is a novel, purified, rheologic and antithrombotic compound, purified poloxamer 188, which ANX is developing as ANX-188. Initially, ANX is developing ANX-188 as a first-in-class treatment for pediatric patients with sickle cell disease in acute crisis and, if ANX is able to reach agreement with FDA on a study protocol on a timely basis, ANX may initiate a Phase 3 clinical trial of ANX-188 for that indication in 2012." Mr. Silver concludes, "In November 2010, ANX submitted a new drug application, or NDA, for Exelbine™, or ANX-530, a novel emulsion formulation of the chemotherapy drug vinorelbine (Navelbine®), to the U.S. Food and Drug Administration, or FDA, and in January 2011, ANX announced that the FDA accepted the Exelbine™ NDA for filing and established a Prescription Drug User Fee Act, or PDUFA, goal date of September 1, 2011 to finish its review of the Exelbine™ NDA."

To download a FREE copy of the ADVENTRX Pharmaceuticals, Inc. research report, please visit http://www.vistapglobal.com and click the "download research" icon to gain access to the report.

About Vista Partners:

Vista Partners LLC, founded in 2005, is a Registered Investment Advisor in the States of California and Oregon. The firm's professional staff has backgrounds in finance, corporate communications and investment banking. Vista Partners LLC has built a name for itself in the small cap space due to its selection of profitable investment ideas.

Disclaimer & Disclosure:

For a full list of disclaimers and disclosures, please visit our website www.vistapglobal.com or click here.

Contact:
877.215.4813 or info@vistapglobal.com


'/>"/>
SOURCE Vista Partners
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
2. Synvista Therapeutics Alagebrium Shows Potential for use in Treating Diabetes-Related Gastrointestinal Complications
3. Synvista Therapeutics Highlights New Data Demonstrating the Clinical Benefit of Vitamin E Therapy in Patients Identified on the Basis of Haptoglobin Phenotype Testing
4. Synvista Collaboration Demonstrates in Preclinical Studies the Mechanism for Defective Cholesterol Transport in Patients with Diabetes
5. Synvista Announces New Data Showing Haptoglobin Type Predicts Effectiveness of Tight Glycemic Control on Cardiovascular Outcomes in Patients with Diabetes
6. Synvista Therapeutics Announces Initiation of Phase 2 Study With Alagebrium for Chronic Heart Failure
7. NeoVista, Inc. Presents New Data on Its Novel Wet AMD Therapy at AAO
8. Siemens Healthcare Diagnostics Launches B12, Folate, and Ferritin Tests on Its Dimension vista Intelligent Lab System
9. NeoVista Presents One Year Data on Novel Wet AMD Therapy at Macula Society
10. Synvista Therapeutics Presents New Preclinical Data Demonstrating the Value of Haptoglobin Genotype Testing In Diabetes at ACC Scientific Sessions
11. FDA Grants NeoVistas Request to Expand CABERNET Trial to 30 Sites in the U.S.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2017)... 2017 A new Transparency Market Research report ... valued at US$0.53 bn in 2013 and is predicted to touch ... between 2014 and 2022. The title of the report is "Non-invasive ... Growth, Trends and Forecast 2014 - 2022." ... Non-invasive prenatal testing (NIPT), also referred to ...
(Date:1/23/2017)... SAN DIEGO , 23 janvier 2017  ResMed ... Winter Haven , Floride) ont annoncé aujourd,hui qu,ils se ... les litiges existants entre les parties. BMC et 3B ... de paiements de droits à ResMed, et ResMed effectuera ... à 3B pour clore le litige de Floride entre ...
(Date:1/23/2017)... , Jan 23, 2017 NeuroVive Pharmaceutical ... has signed a preclinical collaboration agreement with the Children,s Hospital ... J. Falk , M.D., a US key opinion leader in ... ... will evaluate compounds from NeuroVive,s research program, NVP015, in certain ...
Breaking Medicine Technology:
(Date:1/23/2017)... ... January 23, 2017 , ... ... training standards for healthcare treatment providers who treat the full spectrum of eating ... , The Presidents Council consists of the leading eating disorder treatments centers ...
(Date:1/23/2017)... ... January 23, 2017 , ... The American Academy ... the scientific development, healthcare training and clinical application of medical infrared imaging, has ... Member Certification Qualification Courses for Technicians, respectively. , For the first time the ...
(Date:1/23/2017)... Portland, Oregon (PRWEB) , ... January 23, 2017 ... ... systems, announced today it has earned organic certification under the USDA National Organic ... the USDA Organic Certification process, we have established organic production and handling systems ...
(Date:1/23/2017)... ... January 23, 2017 , ... ... gynecological care and gynecological services for women of all ages. The ... a wide variety of reproductive services from routine health screenings to diagnosing and ...
(Date:1/23/2017)... , ... January 23, 2017 , ... “Life Under Blankets”: ... depression from an early age. “Life Under Blankets” is the creation of published author, ... Illinois, Circle Campus in Chicago. She went on to pursue a master’s degree in ...
Breaking Medicine News(10 mins):